| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| A598 | CDP-571 Featured |
|
|
| A599 | CMAB008 Featured |
|
|
| A600 | Epitomics patent anti-TNFα Featured |
|
|
| A601 | ESBA-105 Featured |
|
|
| A602 | Anti-TNFSF2/TNFa Antibody (hMAK195) Featured |
|
|
| A603 | Oxelumab Featured | Oxelumab (R 4930) is a human monoclonal antibody against the OX40 ligand (OX40L). Oxelumab can be used for the research of asthma. |
|
| A604 | Amlitelimab Featured | Amlitelimab () is an anti-OX40 Ligand (OX40L) monoclonal antibody (mAb). Amlitelimab inhibits OX40-OX40L interaction, and can be used in the research of atopic dermatitis. |
|
| A605 | Ruplizumab Featured | Ruplizumab (BG 9588) is a humanized monoclonal anti-CD40L (TNF Receptor) IgG1κ antibody. Ruplizumab has the potential for systemic lupus erythematosus disease research. |
|
| A606 | Dapirolizumab Featured | Dapirolizumab is a monoclonal antibodi against CD40 ligand. Dapirolizumab targets CD40L, blocks its interaction with CD40 receptors, and inhibits adaptive immune activation. Dapirolizumab attenuates systemic lupus erythematosus. |
|
| A607 | Vorsetuzumab Featured | Vorsetuzumab (Anti-Human CD70 Recombinant Antibody) is a human anti-CD70 antibody. Vorsetuzumab enhances macrophage-related phagocytosis of renal carcinoma cells, shows inhibitory efficacy against Burkitt’s lymphoma. |
|
| A608 | Cusatuzumab Featured | Cusatuzumab is a human αCD70 monoclonal antibody. Cusatuzumab shows cytotoxicity activity with enhanced antibody-dependent cellular. Cusatuzumab reduces leukemia stem cells (LSCs) and triggers gene signatures related to myeloid differentiation and apoptosis. Cusatuzumab has the potential for the research of Acute myeloid leukemia (AML). |
|
| A609 | Abbvie patent anti-TNFSF9 Featured |
|
|
| A610 | Naptumomab Featured | Naptumomab is a fusion protein of a tumor-targeting superantigen (TTS). Naptumomab stimulates the immune system to recognize and kill tumor cells and can be used in the study of refractory solid tumors such as renal cell carcinoma. |
|
| DC67110 | DOTMA | DOTMA is a cationic lipid that has been used as a non-viral vector for gene therapy. DOTMA is used as a component of liposomes to encapsulate siRNA, microRNA, and oligonucleotides and for in vitro gene transfection. DOTMA promotes effective interaction between liposomes and cell membranes by inducing positive charge on the liposomes. DOTMA showed good gene transfection effect both in vitro and in vivo. |
|
| DC67111 | 18:1 PEG2000 PE Featured | 18:1 PEG2000 PE (18:1 PEG-PE) is a polyethyleneglycol/phosphatidyl-ethanolamine conjugate. 18:1 PEG2000 PE can be used for drug delivery. |
|
| DC67112 | DPPE-PEG2000 Featured | DPPE-PEG2000 (16:0 PEG2000 PE) is a PEG-modified lipids. 16:0 PEG2000 PE can reduce the nonspecific adsorption of protein and prolong circulation time in vivo. |
|
| DC67113 | DPPE-DBCO Featured |
|
|
| DC67114 | Lecithin Hydrogenated |
|
|
| A611 | ASN004 Featured |
|
|
| A612 | Anti-TPBG Antibody (PF-06263507) Featured |
|
|
| A613 | Wyeth patent anti-5T4 Featured |
|
|
| A614 | Genentech patent anti-Tryptase Beta 1 Featured |
|
|
| A615 | PY159 Featured |
|
|
| A616 | PY314 Featured |
|
|
| A617 | GBR-900 Featured |
|
|
| A618 | Rinat patent anti-TrkB Featured |
|
|
| A620 | Sacituzumab Featured | Sacituzumab is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab is used for the synthesis of antibody-drug conjugates (ADC) drugs. Antibody-drug conjugates with sacituzumab (sacituzumab govitecan) (HY-132254) targeting TROP-2 have been approved for the field of triple-negative breast cancer. |
|
| A621 | Flanvotumab Featured | Flanvotumab (IMC-20D7S) is a human monoclonal antibody targeting to tyrosinase-related protein (TYRP1), specifically expressed in melanocytes and melanoma cells. Flanvotumab acts function via natural killing-mediated antibody-dependent cell-mediated cytotoxicity (ADCC). Flanvotumab has potent anti-tumor activity and good tolerance. |
|
| A622 | Anti-TSHR Antibody (K1-70) Featured |
|
|
| A623 | Schering patent anti-TSLP Featured |
|
